Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) recently announced promising preliminary results from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor being developed for Familial Adenomatous Polyposis (FAP). This rare genetic disorder, caused by mutations in the APC gene, leads to the growth of numerous gastrointestinal polyps and poses a near 100% risk of colorectal cancer if untreated. The study revealed a median 43% reduction in polyp burden among six patients after 13 weeks, with 83% experiencing reductions between 31% and 82%. Additionally, half of the patients showed an improvement in Spigelman stage, indicating reduced upper GI disease severity. The safety profile of REC-4881 was generally consistent with previous MEK1/2 inhibitors, mostly resulting in mild to moderate adverse events. These encouraging results provide hope for the 50,000 individuals affected by FAP in the US and EU5, who currently have no FDA-approved treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.